FDA Commissioner Marty Makary, M.D.

Industry Insights – May 2026

Biosimilars are gaining U.S. momentum even as patent thickets keep triggering legal fights, small biotechs are feeling the pressure of the FDA’s faster-moving approval environment, and the agency is testing real-time clinical trial review with big-name drugmakers already on board. It’s a fast-changing drug-development landscape worth watching. Don’t miss the Read more

By Jason Shaneyfelt, ago